🚀
Enjoy a 7-Day Free Trial Thru May 06, 2024!
✨
Sign Up
Login
Free Sign-up
Login
7-Day Free Trial
Home
Homepage
Membership Levels
About Us
General Discussion
Complete Stock List
The book
Membership Data Coverage
Founder's Message
Free Trial
Referral Program
Partner Program
GuruFocus Podcast
Screeners
GuruFocus Screeners
All-In-One Screener
Ben Graham Lost Formula
Canadian Faster Growers
CEO Buys
CEO Buys after Price Drop > 20%
Dividend Kings 2023
Dividend Aristocrats 2023
Dividend Growth Portfolio
Dividend Income Portfolio
Fast Growers
Good Companies
Hedge Fund Guru Top 10 Aggregated
High Quality
High Quality Low Capex w ROE ROC min
High Quality & Low Capex
High Yield Insider Buys
Historical High Dividend Yields
International Gurus' Top Holdings
James Montier Short Screen
Margin Decliners
Mega Caps
Peter Lynch & Warren Buffett
Peter Lynch Growth w Lower Valuation
Peter Lynch S&L Traded Below Book
PFCF Screener
Piotroski Score Screener
Predictable Growth Companies
Profitable predictable margin expanders
Stocks Sold w less Cash
The Stalwarts
My Screeners
Create My Screener
Value Screens
Stock Ideas
All-In-One Screener
S&P 500 Map
S&P 500 Bubble
S&P 500 Aggregate
Buffett-Munger Screener
Industry Overview
Undervalued Predictable
Benjamin Graham Net-Net
52-week/3Y/5Y Lows
52-week/3Y/5Y Highs
Magic Formula(Greenblatt)
Dividend Stocks
Peter Lynch Screen
S&P500 Grid
Predictable Companies
Spin Off List
Merger and Acquisition List
Historical Low P/B List
Historical Low P/S List
High Short Interest
Upcoming Special Dividends
Delisted Stocks
Model Portfolios
Performances Overview
Most Broadly Held Portfolio
Most Weighted Portfolio
Buffett-Munger Top 25
GF Score <= 100 Top 25
Top 25 Undervalued Predictable
Top 25 52-week Low Predictable
Top 25 Historical Low P/S
Stock Comparison
Airline Stocks
Artificial Intelligence Stocks
Bank Stocks
Biotech Stocks
Blockchain Stocks
Chinese Stocks
Dividend Stocks
EV Stocks
Growth Stocks
Oil Stocks
Value Stocks
Virtual Reality Stocks
Compare More Stocks…
Gurus
Guru Trades
Latest Guru Picks
Real Time Picks
Guru Portfolio
Score Board
Mutual Funds
Top 10 Holdings
Sector Picks
International Picks
Aggregated Portfolio
Consensus Picks
Guru Bargains
Hot Picks
Download Guru Portfolios
Industry Trends
Geographic Trend
ETFs
Options Holdings
European Shorting
Guru Lists
Complete Guru List
Warren Buffett
Bill Gates
Mohnish Pabrai
Carl Icahn
George Soros
David Tepper
Seth Klarman
Bill Ackman
Joel Greenblatt
Charlie Munger
Michael Price
Julian Robertson
Chuck Akre
David Einhorn
Tom Gayner
My Guru Lists
Insiders
Insider Trading Tracker
Real-Time Insider Picks
CEO Buys/Sells
CFO Buys/Sells
Insider Trends
Insider Cluster
Guru + Insider Double Buys
Triple Buys/Sells
Chinese Insider
German Insider
Complete Insider List
Politician Trading Tracker
Real-Time Politician Picks
Complete Politician List
Nancy Pelosi
Mitch Mcconnell
Tommy Tuberville
Josh Gottheimer
Kevin Hern
Thomas R. Carper
Susie Lee
Lois Frankel
Market
US Market Valuation
Buffett Indicator
U.S. Treasury Yield Curve
U.S. Inflation Rate
Presidential Cycle and Stock Market
Shiller P/E
Shiller P/E by Sectors
GF Value for S&P 500 Index
Fed Net Liquidity
Buffett Assets Allocation
Latest IPOs
Global Market Valuation
Global Market Overview
USA
China
Japan
India
Canada
UK
France
Germany
Brazil
Australia
More...
Economic Indicators
Economic Indicators Overview
The Dow Jones Industrial Average (DJIA)
SP 500 Index
Nasdaq Composite Index
Gross Domestic Product (GDP)
Shiller PE
Ratio of Wilshire 5000 over GNP
Civilian Unemployment Rate
Russell 2000 Index
CBOE Volatility Index (VIX)
Total Nonfarm Payrolls: All Employees
More...
Sector & Industry Performance
Global Industry Overview
USA
Asia
Europe
Canada
UK/Ireland
Oceania
Latin America
Africa
India/Pakistan
Articles
Articles
Editors' Picks
Stock Market News
Q&A with Gurus
Guru Stock Picks
Insider Transaction
Earning Reports
CEO Shareholder Letters
Podcast
Earnings Call Transcripts
Software Stock News
Biotechnology Stock News
Hardware Stock News
Banks Stock News
Metals & Mining Stock News
Drug Manufacturers Stock News
All Articles
Submit Articles
Submit Article Online
Contributor Guidelines
Tools
Model Portfolios
All-In-One Screener
Data Batch Download
Guru Portfolio Download
Insider Data Download
Excel Add-In
Google Sheets Add-On
API
Manual of Stocks
DCF Calculator
WACC Calculator
Interactive Chart
Maps
Fund Letters Archive
Stock Comparison Table
Mobile App
Discussion Board
GuruGPT
Financial Calendar
Embed Widgets
Stock Market Holidays
Discussion
Discussion Board
GuruFocus Discord
ETF
Data
Pricing
Tutorials
Tutorials
Financial Glossary
FAQ
Change Log
Contact Us
Support
Chat Support
Create a ticket
Book Demo
User Engagement Meeting
469-248-6885
Status
Take Survey
Ask the community in Discord
Subscribe
Free Trial
Group Subscription
Refer a Friend and Earn One Month of Free Membership
GURUFOCUS.COM
STOCK LIST
Healthcare
Biotechnology
Humanigen Inc (OTCPK:HGENQ)
News
Humanigen Inc
OTCPK
:HGENQ (USA) Â
$ 0.00
-0.0065 (-97.01%)
10:08 PM EST
P/E:
At Loss
P/B:
0
Market Cap:
$ 24.00K
Enterprise V:
$ -21.64M
Volume:
48.49K
Avg Vol (2M):
28.32K
Warning! GuruFocus detected issues with HGENQ.
Try a 7-Day Free Trial
to check it out.
Also Trade In:
Volume:
48.49K
Market Cap $:
24.00K
PE Ratio:
At Loss
Avg Vol (2M):
28.32K
Enterprise Value $:
-21.64M
PB Ratio:
0
Alerts
Website
SEC Filings
Stock PDF
Dataset
Financial Download
Manual of Stocksâ„¢
Compare
0
Summary
30-Y Financials
DCF
Dividend
Guru Trades
Insider
Interactive Chart
Filings
Transcripts
News
Compare
Stock PDF
Ownership
Operating
Checklist
Vote
Definitions
Humanigen Inc (OTCPK:HGENQ) Stock News, Headlines & Updates
Humanigen Inc Stock News from GuruFocus
Total 128
1
2
3
4
Feb 13, 2024
Humanigen Inc at H C Wainwright Global Investment Conference (Virtual) Transcript
GuruFocus Research
•
2:50pm
Humanigen Inc at Lytham Partners Summer Investor Conference (Virtual) Transcript
GuruFocus Research
•
2:50pm
Humanigen Inc at Jefferies Healthcare Conference Transcript
GuruFocus Research
•
2:50pm
Humanigen Inc Annual Shareholders Meeting Transcript
GuruFocus Research
•
2:50pm
Humanigen Inc at Guggenheim Vaccine and Infectious Disease Conference (Virtual) Transcript
GuruFocus Research
•
2:50pm
Humanigen Inc at JPMorgan Healthcare Conference (Virtual) Transcript
GuruFocus Research
•
2:50pm
Oct 25, 2022
HGEN FINAL DEADLINE TODAY: ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Humanigen, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important October 25 Deadline in Securities Class Action – HGEN
Value_Insider
•
10:00am
Oct 24, 2022
HGEN, CPNG & SFIX Class Action Deadlines: Bronstein, Gewirtz & Grossman, LLC, A Top Class Action Firm, Reminds Investors of Last Day to Actively Participate
Value_Insider
•
12:00pm
Oct 22, 2022
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment Humanigen, Inc. of Class Action Lawsuit and upcoming Deadline – HGEN
Value_Insider
•
5:00pm
Oct 20, 2022
HGEN FINAL DEADLINE NOTICE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Humanigen, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important October 25 Deadline in Securities Class Action – HGEN
Value_Insider
•
4:00pm
Oct 19, 2022
Humanigen, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses; Last day to actively participate in the case; October 25, 2022
Value_Insider
•
7:00am
Oct 18, 2022
HUMANIGEN, INC. (NASDAQ: HGEN) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Humanigen, Inc. (NASDAQ: HGEN)
Value_Insider
•
1:00am
Oct 15, 2022
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Humanigen, Inc. of Class Action Lawsuit and upcoming Deadline – HGEN
Value_Insider
•
8:00pm
Oct 14, 2022
HGEN, CPNG & SFIX Class Actions: Bronstein, Gewirtz & Grossman, LLC, A Leading Class Action Firm, Reminds Investors to Contact the Firm and Actively Participate
Value_Insider
•
12:00pm
Sep 01, 2022
Moore Kuehn, PLLC Encourages Investors of Humanigen, Inc. to Contact Law Firm
Ds***
•
11:00am
Aug 31, 2022
HUMANIGEN, INC. CLASS ACTION ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the United States District Court for the District of New Jersey against Humanigen, Inc.
Ds***
•
5:00pm
HUMANIGEN, INC. (NASDAQ: HGEN) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Humanigen, Inc. (NASDAQ: HGEN)
Ds***
•
3:00pm
Aug 29, 2022
Humanigen Class Action Complaint Filed: Johnson Fistel, Globally-Recognized Law Firm Encourages Shareholders to Submit Their HGEN Losses
Ds***
•
10:00am
Aug 26, 2022
Pomerantz Law Firm Announces the Filing of a Class Action Against Humanigen, Inc. and Certain Officers – HGEN
PurpleRose
•
5:00pm
Jul 18, 2022
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Humanigen, Inc. - HGEN
PurpleRose
•
3:00pm
Jul 22, 2021
Humanigen's Partner in South Korea Receives Ministry of Food and Drug Safety (MFDS) Approval to Conduct Phase 1 Study of Lenzilumab
Business Wire
•
9:00am
Jul 09, 2021
UK's MHRA accepts Humanigen's submission of Lenzilumab for Marketing Authorization in COVID-19 for expedited rolling review
Business Wire
•
6:00am
Jun 14, 2021
Humanigen Initiates Submission for Lenzilumab Marketing Authorization in COVID-19, to the United Kingdom's Medicines and Healthcare Products Regulatory Agency (MHRA)
Business Wire
•
6:00am
Jun 07, 2021
Humanigen Announces Ken Trbovich Appointed as Senior Vice President, Investor Relations
Business Wire
•
8:00am
Jun 03, 2021
Humanigen to Present at the 2021 LD Micro Invitational XI
Business Wire
•
8:00am
May 28, 2021
Humanigen Submits Application to FDA for Emergency Use Authorization for Lenzilumab in COVID-19
Business Wire
•
9:00am
May 26, 2021
GM-CSF Gene-Edited CAR-T Data to be Presented at International Society for Cell & Gene Therapy Annual Meeting 2021
Business Wire
•
8:01am
May 19, 2021
Humanigen to Present at Jefferies Healthcare Conference
Business Wire
•
7:00am
May 17, 2021
Humanigen and Chime Biologics Enter Into Manufacturing Agreement for COVID-19 Therapeutic Candidate Lenzilumab
Business Wire
•
8:01am
May 13, 2021
Humanigen Reports First Quarter 2021 Financial Results
Business Wire
•
4:00pm
May 05, 2021
Humanigen Announces Publication of Results From Phase 3 Randomized Double-Blind Placebo-Controlled Study Demonstrating the Efficacy and Safety of Lenzilumabâ„¢ in Hospitalized COVID-19 Patients
Business Wire
•
11:00am
Apr 21, 2021
Humanigen Appoints Dr. Adrian Kilcoyne to the role of Chief Medical Officer
Business Wire
•
7:00am
Apr 19, 2021
Humanigen Reports Positive Data With Lenzilumab in the ZUMA-19 CAR-T Phase 1b Study in DLBCL and Plans to Initiate a Potential Registrational Study
Business Wire
•
7:00am
Mar 11, 2021
Humanigen Reports Fourth Quarter and Year-End 2020 Financial Results and Provides Corporate Update
Business Wire
•
7:01pm
Humanigen Announces $80 Million Loan Facility from Hercules Capital
Business Wire
•
7:00pm
Mar 06, 2021
Humanigen to Present at Roth Conference
Business Wire
•
7:00pm
Mar 02, 2021
Humanigen Expands its anti-GM-CSF Patent Portfolio
Business Wire
•
7:01am
Feb 25, 2021
Humanigen to Present at Multiple Investor Conferences in March
Business Wire
•
7:00am
Feb 11, 2021
Humanigen to Present and Participate at Multiple Upcoming Investor and Industry Conferences
Business Wire
•
7:00am
Feb 08, 2021
Humanigen Elects Dr. Dale Chappell to Board of Directors
Business Wire
•
7:00am
Total 128
1
2
3
4
Show
20
40
60
80
100
No data
Entries
Headlines
Total 0
1
No recent news